Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ranitidine hydrochloride-induced hypergastrinemia.

J C Chisholm

    Journal of the National Medical Association
    |April 1, 1985
    PubMed
    Summary

    This study examined the effects of ranitidine hydrochloride on gastrin levels in a patient. Despite being marketed as a drug that does not significantly increase gastrin, the study found that ranitidine caused a notable rise in serum gastrin levels. The elevation persisted for several days after the drug was stopped. These findings suggest that ranitidine may not be as neutral to gastrin levels as previously thought. The results highlight the need for further research and possible changes in clinical guidelines for drug use.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Relapsed rhabdomyosarcoma: treatment recommendations from the European pediatric soft tissue sarcoma study group (EpSSG).

    British journal of cancer·2025
    Same author

    'It's Skin Cancer'… a Rollercoaster of a Journey for Teenagers, Young People and Their Significant Other.

    Journal of advanced nursing·2025
    Same author

    Endocrine disorders among long-term survivors of childhood head and neck rhabdomyosarcoma.

    European journal of cancer (Oxford, England : 1990)·2015
    Same author

    Successful introduction and audit of a step-down oral antibiotic strategy for low risk paediatric febrile neutropaenia in a UK, multicentre, shared care setting.

    European journal of cancer (Oxford, England : 1990)·2009
    Same author

    Efficacy of carboplatin given in a phase II window study to children and adolescents with newly diagnosed metastatic soft tissue sarcoma.

    European journal of cancer (Oxford, England : 1990)·2007
    Same author

    Treating low-risk febrile neutropenia: Jenny's story.

    Archives of disease in childhood·2006

    Area of Science:

    • Gastroenterology
    • Pharmacology
    • Endocrinology

    Background:

    Hypergastrinemia is a known condition associated with various gastrointestinal and pharmacological factors. Prior research has shown that certain drugs, particularly H2-receptor antagonists, can influence gastrin levels in the bloodstream. However, ranitidine hydrochloride has been marketed as a drug that does not significantly elevate serum gastrin concentrations. This gap motivated the investigation of whether ranitidine can cause unexpected gastrin increases in clinical settings. No prior work had resolved the discrepancy between clinical claims and observed outcomes. The mechanism of gastrin regulation remains complex, involving multiple physiological and pharmacological interactions. Understanding these interactions is essential for managing drug-induced hormonal imbalances. This paper's contribution lies in presenting a case that challenges the assumed safety profile of ranitidine. The findings may help refine clinical guidelines for drug use in patients with gastrin-related conditions.

    Purpose Of The Study:

    Keywords:
    ranitidine gastrin effectsH2-receptor antagonistgastrin elevationpharmacological impact

    Frequently Asked Questions

    The study reports that ranitidine may cause significant acute hypergastrinemia in some patients.

    The study observed that gastrin levels remained elevated for several days after discontinuation of the drug.

    The authors suggest that elevated gastrin levels may have clinical implications, necessitating monitoring in patients on ranitidine.

    The findings challenge the marketed safety profile of ranitidine regarding gastrin levels and suggest a need for further clinical evaluation.

    Related Experiment Videos

    This study aimed to investigate the potential of ranitidine hydrochloride to induce hypergastrinemia despite its marketed safety profile. The specific problem addressed was the observed discrepancy between clinical claims and patient outcomes. The motivation stemmed from a need to clarify the drug's effects on gastrin levels. The study focused on a single case where ranitidine was administered and gastrin levels were monitored. The goal was to determine if the drug could cause significant gastrin elevation in real-world use. The authors sought to evaluate the duration of this effect after drug discontinuation. By analyzing this case, the study aimed to contribute to the understanding of ranitidine's pharmacological impact. The findings could inform safer prescribing practices for patients at risk of gastrin-related complications.

    Main Methods:

    The study employed a case-based observational approach to assess ranitidine's effects on serum gastrin levels. A single patient was monitored before, during, and after ranitidine administration. Blood samples were collected at multiple time points to measure gastrin concentrations. The drug was administered according to standard clinical protocols. Serum gastrin levels were quantified using standard laboratory techniques. The study design allowed for tracking changes in gastrin levels over time. No additional interventions were introduced to isolate ranitidine's effects. The results were analyzed to determine the magnitude and duration of gastrin elevation.

    Main Results:

    The administration of ranitidine hydrochloride led to a significant increase in serum gastrin levels. This acute hypergastrinemia was observed within a short period after drug intake. The gastrin elevation remained elevated for several days following discontinuation of the drug. The magnitude of the increase exceeded typical baseline levels. The duration of the effect suggested a prolonged pharmacological impact. These findings contradict the drug's marketed safety profile regarding gastrin. The results were consistent with the observed clinical response in the patient. The study provides evidence that ranitidine may not be as neutral to gastrin levels as previously assumed.

    Conclusions:

    The authors propose that ranitidine hydrochloride may cause significant hypergastrinemia in some patients. This finding challenges the assumption that the drug does not elevate gastrin levels. The observed effect was sustained even after drug discontinuation. The study highlights the importance of monitoring gastrin levels in patients using ranitidine. The results suggest that clinical guidelines may need to be reevaluated. The authors emphasize the need for further research on ranitidine's effects in larger populations. These conclusions are based on the observed case and its implications. The findings may contribute to improved patient management strategies.

    Serum gastrin levels were measured using standard laboratory techniques at multiple time points.

    The study suggests that clinicians should consider gastrin monitoring in patients prescribed ranitidine hydrochloride.